Hematologic Oncology

Novel agents such as momelotinib and pacritinib are expanding the myelofibrosis treatment landscape, and additional research will further define the options available for patients with this disease, as well as those with other leukemias and lymphomas.

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma.

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

The first patient in the chronic lymphocytic leukemia cohort has been dosed in the phase 1 COVALENT-101 trial, which is evaluating the first-in-class covalent menin inhibitor BMF-219.

The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma.

Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

The FDA has accepted and granted priority review to the new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.

Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.

Pei-Ling Chen, MD, PhD, says management of cutaneous T-cell lymphoma requires a multidisciplinary team of specialists including dermatologists and radiation oncologists.

Pei-Ling Chen, MD, PhD, discusses epidemiology and racial disparities in CTCL.

Pei-Ling Chen, MD, PhD, discusses the incidence of CTCL.

Drs DiNardo, Wang, and Altman discuss the challenges they faced in their early careers, the rollout of molecular profiling and targeted therapy in the early 2000s, and their growth from protégés to mentors.

Farrukh Awan, MD, discusses transplant and chemotherapy options in frontline diffuse large B-cell lymphoma, the emergence of CAR T-cell therapy in relapsed diffuse large B-cell lymphoma, and available targeted therapies in acute myeloid leukemia.

The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.

The FDA has granted an orphan drug designation to PCLX-001 for the treatment of patients with acute myeloid leukemia.

Praveen Ramakrishnan, MD, MS, discusses the evolution of diffuse large B-cell lymphoma treatment, the implications of key phase 3 studies, and how emerging bispecific T-cell engagers and antibody-drug conjugates may increase treatment accessibility beyond the limitations of CAR T-cell therapy for patients at various disease stages.